Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19354579 | 0.84 | — | — | |
| SCHEMBL1522730 | 0.84 | — | — | |
| SCHEMBL19690771 | 0.80 | — | — | |
| SCHEMBL2044222 | 0.76 | SMN1; SMN2 (0.43) | KDM4EHTTTSHRALDH1A1MEN1 | |
| SCHEMBL28181487 | 0.74 | SMN1; SMN2 (0.42) | KDM4EHTTTSHRALDH1A1MEN1 | |
| SCHEMBL9396417 | 0.74 | HSD17B10 (0.39) | KDM4EHTTTSHRALDH1A1KMT2A | |
| SCHEMBL2041571 | 0.74 | KDM4E (0.42) | KDM4EHTTTSHRALDH1A1MEN1 | |
| SCHEMBL15274538 | 0.73 | TSHR (0.39) | KDM4EHTTTSHRALDH1A1MEN1 | |
| SCHEMBL7010502 | 0.73 | DRD2 (0.47) | — | |
| SCHEMBL2068342 | 0.72 | MAPT (0.40) | KDM4EHTTTSHRALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2013544281-A | — | — | 2013-12-12 | — | — | JP | disclosed |
| EP-2657231-A2 | SUBSTITUTED AZOLES, ANTI-VIRAL ACTIVE INGREDIENT, PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF | Ivachtchenko, Alexandre Vasilievich (US) | 2013-10-30 | — | — | EP | disclosed |
| US-20130253008-A1 | SUBSTITUTED AZOLES, ANTIVIRAL ACTIVE COMPONENT, PHARMACEUTICAL COMPOSITION, METHOD FOR PREPARATION AND USE THEREOF | ALLA CHEM LLC (US) | 2013-09-26 | — | — | US | disclosed |
| WO-2012074437-A3 | SUBSTITUTED AZOLES, ANTI-VIRAL ACTIVE INGREDIENT, PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF | АЛЛА ХЕМ, ЛЛС (US) | 2012-09-13 | — | — | WO | disclosed |
| CN-1738828-B | Avermectin b1 and avermectin b1 monosaccharide derivatives having an alkoxymethyl substituent in the 4''- or 4'-position | MERIAL LTD | 2012-09-05 | — | — | CN | disclosed |
| WO-2012074437-A2 | SUBSTITUTED AZOLES, ANTI-VIRAL ACTIVE INGREDIENT, PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF | АЛЛА ХЕМ, ЛЛС (US) | 2012-06-07 | — | — | WO | disclosed |
| CN-1738828-A | Avermectin b1 and avermectin b1 monosaccharide derivatives having an alkoxymethyl substituent in the 4''- or 4'-position | SYNGENTA PARTICIPATIONS AG (CH) | 2006-02-22 | — | — | CN | disclosed |
| US-20040179770-A1 | Polarisation independent optical switch | QINETIQ LIMITED | 2004-09-16 | — | — | US | disclosed |
| US-5466691-A | Antipsychotic and anxiolytic agents | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1995-11-14 | — | — | US | disclosed |
| EP-0596120-A1 | THIOPHENE COMPOUND | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1994-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130253008-A1 | SUBSTITUTED AZOLES, ANTIVIRAL ACTIVE COMPONENT, PHARMACEUTICAL COMPOSITION, METHOD FOR PREPARATION AND USE THEREOF | HCCS, EIF2AK2, HAVCR2 | KDM4E 1508/4885HTT 4659/4885TSHR 1510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.